검색어 : 통합검색[Paris Massimo]
총 985건 중 985건 출력
, 91/99 페이지
-
901
- Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas
- Thouvenin, Jonathan; Alhalabi, Omar; Carlo, Maria; Carril-Ajuria, Lucia; Hirsch, Laure; Martinez-Chanza, Nieves; Né grier, Sylvie; Campedel, Luca; Martini, Dylan; Borchiellini, Delphine; Chahoud, Jad; Lodi, Massimo; Barthé lé my, Philippe; Hasanov, Elshad; Hahn, Andrew W; Gil, Thierry; Viswanathan, Srinivas R; Bakouny, Ziad; Msaouel, Pavlos; Asim Bilen, Mehmet; Choueiri, Toni K; Albiges, Laurence; Tannir, Nizar M; Malouf, Gabriel G; MD Anderson Cancer Center (MDACC) , Houston, TX , USA; Memorial Sloan Kettering Cancer Center , New York, NY , USA; Institut Gustave Roussy , Villejuif , France; Dana-Farber Cancer Institute (DFCI) , Boston, MA , USA; Institut Jules Bordet , Bruxelles , Belgium; Université Claude Bernard, Centre Lé on Bé rard , Lyon , France; AP-HP, Groupe hospitalier Pitié -Salpê triè re , Paris , France; Winship Cancer Institute of Emory University , Atlanta, GA , USA; Antoine Lacassagne Cancer Center , Nice , France; Department of Genitourinary Oncology, Moffitt Cancer Center , Tampa, FL , USA; Institut de Cancé rologie Strasbourg Europe (ICANS/HUS) , Strasbourg , France; (The oncologist, v.27, 2022, pp.1041-1047)
-
902
- Asciminib (ASC) in Combination with Imatinib (IMA), Nilotinib (NIL), or Dasatinib (DAS) May be a Potential Treatment (Tx) Option in Patients (Pts) with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase or Accelerated Phase (Ph+ CML-CP/AP): Final Results from the Asciminib Phase 1 Study
- Cortes, Jorge; Lang, Fabian; Rea, Delphine; Hochhaus, Andreas; Breccia, Massimo; Goh, Yeow Tee; Heinrich, Michael C.; Hughes, Timothy P; Janssen, Jeroen J.W.M.; le Coutre, Philipp; Minami, Hironobu; Sasaki, Koji; DeAngelo, Daniel J.; Sanchez-Olle, Gessami; Pognan, Nathalie; Jose, Jomy; Hoch, Matthias; Mauro, Michael; 1Georgia Cancer Center, Augusta University, Augusta, GA; 2Hematology/Oncology, Klinikum der Goethe Universitä t, Frankfurt/Main, Germany; 3Hematology Department, Hô pital Saint-Louis, Paris, France; 4Universitä tsklinikum Jena, Jena, Germany; 5Department of Translational and Precision Medicine, Hematology-Sapienza University, Rome, Italy; 6Department of Hematology, Singapore General Hospital, Singapore, Singapore; 7Department of Medicine, Division of Hematology and Oncology, Portland VA Health Care System and Oregon Health & Science University, Knight Cancer Institute, Portland, OR; 8South Australian Health and Medical Research Institute (SAHMRI), Adelaide, Australia; 9Department of Hematology, Amsterdam University Medical Centers, VUmc, Amsterdam, Netherlands; 10Charité -Universitä tsmedizin Berlin, Berlin, Germany; 11Department of Medical Oncology and Hematology, Kobe University Hospital, Kobe, Japan; 12Department of Leukemia, The University of Texas; (Blood, v.142, 2023, pp.868-868)
-
903
- Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial
- Cortes, Jorge E.; Hughes, Timothy P.; Mauro, Michael J.; Hochhaus, Andreas; Rea, Delphine; Goh, Yeow Tee; Janssen, Jeroen; Steegmann, Juan Luis; Heinrich, Michael C.; Talpaz, Moshe; Etienne, Gabriel; Breccia, Massimo; Deininger, Michael W.; le Coutre, Philipp D; Lang, Fabian; Aimone, Paola; Polydoros, Fotis; Cacciatore, Silvia; Stenson, Laura; Kim, Dong-Wook; Georgia Cancer Center Augusta University, Augusta, GA; South Australian Health and Medical Research Institute SAHMRI, Adelaide, Australia; Myeloproliferative Neoplasms Program, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY; Klinik fü r Innere Medizin II, Jena, Germany; Hopital Saint Louis, Paris, France; Department of Hematology, Singapore General Hospital, Singapore, Singapore; VU University Medical Center, Amsterdam, NLD; Hospital de La Princesa, Madrid, Spain; Portland VA Health Care System, Portland, OR; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Hematology Department, Institut Bergonié , Bordeaux, France; Department of Translational and Precision Medicine, Sapienza University, Rome, Italy; Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT; Charité - Universitä tsmedizin Berlin, Berlin, Germany; Department of Medicine II, Hematology/Oncology, Goethe University, Frankfurt, Germany; (Blood, v.136, 2020, pp.47-50)
-
904
- The current role of next-generation DNA sequencing in routine care of patients with hereditary cardiovascular conditions: a viewpoint paper of the European Society of Cardiology working group on myocardial and pericardial diseases and members of the European Society of Human Genetics
- Mogensen, Jens; van Tintelen, J. Peter; Fokstuen, Siv; Elliott, Perry; van Langen, Irene M.; Meder, Benjamin; Richard, Pascale; Syrris, Petros; Caforio, Alida L.P.; Adler, Yehuda; Anastasakis, Aris; Gimeno, Juan R.; Klingel, Karin; Linhart, Ales; Imazio, Massimo; Pinto, Yigal; Newbery, Ruth; Schmidtke, Joerg; Charron, Philippe; Department of Cardiology, Odense University Hospital, Odense, Denmark; Department of Clinical Genetics, Academic Medical Center, Amsterdam, The Netherlands; Genetic Medicine, University Hospitals of Geneva, Switzerland; The Heart Hospital, University College London Hospitals Trust, London, UK; Department of Genetics, University Medical Centre Groningen, University of Groningen, the Netherlands; Department of Internal Medicine III, University of Heidelberg, Germany; Fonctional Unit of Cardiogenetics and Myogenetics, Hô pital Pitié -Salpê triè re, Paris, France; UCL Institute of Cardiovascular Science, London, UK; Division of Cardiology, Department of Cardiological, Thoracic and Vascular Sciences, University of Padova, Padua, Italy; Chaim Sheba Medical Center, Tel Hashomer and Sackler University, Tel Aviv, Israel; Unit of Inherited Cardiovascular Diseases, 1st Department of Cardiology, Athens University Medical School, Athens, Greece; Department of Cardio; (European heart journal, v.36, 2015, pp.1367-1370)
-
905
- DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers
- de Cubas, Aguirre A.; Korpershoek, Esther; Inglada-Pé rez, Lucia; Letouzé , Eric; Currá s-Freixes, Maria; Ferná ndez, Agustin F.; Comino-Mé ndez, Iñ aki; Schiavi, Francesca; Mancikova, Veronika; Eisenhofer, Graeme; Mannelli, Massimo; Opocher, Guiseppe; Timmers, Henri; Beuschlein, Felix; de Krijger, Ronald; Cascon, Alberto; Rodrí guez-Antona, Cristina; Fraga, Mario F.; Favier, Judith; Gimenez-Roqueplo, Anne-Paule; Robledo, Mercedes; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.; Department of Pathology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands.; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.; Programme Cartes d'Identité des Tumeurs, Ligue Nationale Contre Le Cancer, Paris, France.; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.; Cancer Epigenetics Laboratory, Institute of Oncology of Asturias (IUOPA), HUCA, University of Oviedo, Asturias, Spain.; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.; Familial Cancer Clinic, Veneto Institute of Oncology, Padova, Italy.; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.; Institute of Clinical Chemistry and Laboratory Medicine, Technische Universitä t Dresden, Dres; (Clinical Cancer research : an official journal of the American Association for Cancer Research, v.21, 2015, pp.3020-3030)
-
906
- The role of autologous stem cell transplantation in patients with nodal peripheral T‐cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study
- Park, Steven I.; Horwitz, Steven M.; Foss, Francine M.; Pinter‐ Brown, Lauren C.; Carson, Kenneth R.; Rosen, Steven T.; Pro, Barbara; Hsi, Eric D.; Federico, Massimo; Gisselbrecht, Christian; Schwartz, Marc; Bellm, Lisa A.; Acosta, Mark; Advani, Ranjana H.; Feldman, Tatyana; Lechowicz, Mary Jo; Smith, Sonali M.; Lansigan, Frederick; Tulpule, Anil; Craig, Michael D.; Greer, John P.; Kahl, Brad S.; Leach, Joseph W.; Morganstein, Neil; Casulo, Carla; Shustov, Andrei R.; Levine Cancer Institute, Charlotte, North Carolina; Memorial Sloan Kettering Cancer Center, New York, New York; Yale University, New Haven, Connecticut; University of California Irvine, Irvine, California; Washington University School of Medicine, St. Louis, Missouri; City of Hope, Duarte, California; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois; Cleveland Clinic, Cleveland, Ohio; Centro Oncologico Modenese, Policlinico Modena, Italy; Saint Louis Hospital, Paris, France; MS Biostatistics, LLC, Clermont, Florida; MedNet Solutions, Minnetonka, Minnesota; Spectrum Pharmaceuticals, Inc, Irvine, California; Stanford University Medical Center, Stanford, California; Hackensack University Medical Center, Hackensack, New Jersey; Emory University, Atlanta, Georgia; University of Chicago, Chicago, Illinois; Massachusetts Gene; (Cancer, v.125, 2019, pp.1507-1517)
-
907
- Reduced Intensity Vs. Standard Conditioning Followed By Allogeneic Stem Cell Transplantation for Patients with MDS or Secondary AML: A Prospective, Randomized Phase III Study of the Chronic Malignancies Working Party of the EBMT (RICMAC-Trial)
- Krö ger, Nicolaus; Brand, Ronald; Niederwieser, Dietger; Platzbecker, Uwe; Hü bel, Kai; Weber, Thomas; Robin, Marie; Stelljes, Matthias; Afanasiev, Boris V; Heim, Dominik; Lambertenghi Deliliers, Giorgio; Onida, Francesco; Dreger, Peter; Pini, Massimo; Guidi, Stefano; Volin, Liisa; Gramatzki, Martin; Bethge, Wolfgang A.; Poire, Xavier; Kobbe, Guido; van Os, Marleen; Iacobelli, Simona; de Witte, Theo; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Leiden University Medical Center, Leiden, Netherlands; University Hospital Leipzig, Leipzig, Germany; University Hospital Dresden, Dresden, Germany; University of Cologne, Cologne, Germany; University Hospital Halle (Saale), Halle, Germany; Saint Louis Hospital, Paris, France; University of Muenster, Muenster, Germany; BMT Center of St Petersburg Pavlov State Medical University, St Petersburg, Russia; University Hospital Basel, Basel, Switzerland; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy; University of Heidelberg, Heidelberg, Germany; Hematology and Marrow Transplant, A.O. SS Antonio e Biagio e C. Arrigo, Alessandria-Italy., Alessandria, Italy; Ospedale di Careggi, Firenze, Italy; Helsinki University Central Hospital, Department of Medicine, Helsinki, Finland; Univ; (Blood, v.124, 2014, pp.320-320)
-
908
- The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma
- Opat, Stephen; Tedeschi, Alessandra; Linton, Kim; McKay, Pamela; Hu, Bei; Chan, Henry; Jin, Jie; Sobieraj-Teague, Magdalena; Zinzani, Pier Luigi; Coleman, Morton; Thieblemont, Catherine; Browett, Peter; Ke, Xiaoyan; Sun, Mingyuan; Marcus, Robert; Portell, Craig A.; Ardeshna, Kirit; Bijou, Fontanet; Walker, Patricia; Hawkes, Eliza A.; Mapp, Sally; Ho, Shir-Jing; Talaulikar, Dipti; Zhou, Ke-Shu; Co, Melannie; Li, Xiaotong; Zhou, Wenxiao; Cappellini, Massimo; Tankersley, Chris; Huang, Jane; Trotman, Judith; Monash Health, Monash University, Clayton, Victoria, Australia.; ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.; Division of Cancer Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester Cancer Research Centre, Manchester, United Kingdom.; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom.; Levine Cancer Institute University City, Carolinas Medical Center, Atrium Health, Charlotte, North Carolina.; North Shore Hospital, Auckland, New Zealand.; The First Affiliated Hospital, School of Medicine, Zhejiang University Hangzhou, Zhejiang, China.; Flinders Medical Centre, Bedford Park, South Australia, Australia.; IRCCS Azienda Ospedaliero, Universitaria di Bologna, Bologna, Italy.; WCM Research Alliance, Weill Cornell Medicine, Lake Success, New York.; Service d'Hé matologie-Oncologie, Hô pital Saint-Louis, APHP, Paris, France.; Auckland City Hospital, University of Auckland, Grafton, Auckland, New Zealand.; Pe; (Clinical Cancer research : an official journal of the American Association for Cancer Research, v.27, 2021, pp.6323-6332)
-
909
- Bridging animal and clinical research during SARS-CoV-2 pandemic: A new-old challenge
- Winkler, Martin S.; Skirecki, Tomasz; Brunkhorst, Frank M.; Cajander, Sara; Cavaillon, Jean-Marc; Ferrer, Ricard; Flohé , Stefanie B.; Garcí a-Salido, Alberto; Giamarellos-Bourboulis, Evangelos J.; Girardis, Massimo; Kox, Matthijs; Lachmann, Gunnar; Martin-Loeches, Ignacio; Netea, Mihai G.; Spinetti, Thibaud; Schefold, Joerg C.; Torres, Antoni; Uhle, Florian; Venet, Fabienne; Weis, Sebastian; Scherag, André ; Rubio, Ignacio; Osuchowski, Marcin F.; Department of Anesthesiology, Emergency and Intensive Care Medicine, University of Gö ttingen, Gö ttingen, Robert-Koch-Str. 40, 37085 Gö ttingen, Germany; Laboratory of Flow Cytometry, Centre of Postgraduate Medical Education, Warsaw, Poland; Dept. of Anesthesiology and Intensive Care Medicine & Center for Sepsis Control and Care (CSCC), Jena University Hospital-Friedrich Schiller University, Am Klinikum 1, 07747 Jena, Germany; Department of Infectious Diseases, Faculty of Medicine and Health, Ö rebro University, Sweden; French National Research Agency (ANR), Paris, France; Intensive Care Department and Shock, Organ Dysfunction and Resuscitation Research Group, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, Barcelona, 08035, Spain; Department of Trauma, Hand, and Reconstructive Surgery, University Hospital Essen, University Duisburg-Essen, Hufelandstr. 55, 45147 Essen, Germany; Pediatric Critical Care Un; (EBioMedicine, v.66, 2021, pp.103291)
-
910
- EXpert consensus On Diaphragm UltraSonography in the critically ill (EXODUS): a Delphi consensus statement on the measurement of diaphragm ultrasound-derived parameters in a critical care setting
- Haaksma, Mark E.; Smit, Jasper M.; Boussuges, Alain; Demoule, Alexandre; Dres, Martin; Ferrari, Giovanni; Formenti, Paolo; Goligher, Ewan C.; Heunks, Leo; Lim, Endry H. T.; Mokkink, Lidwine B.; Soilemezi, Eleni; Shi, Zhonghua; Umbrello, Michele; Vetrugno, Luigi; Vivier, Emmanuel; Xu, Lei; Zambon, Massimo; Tuinman, Pieter R.; Department of Intensive Care Medicine, Amsterdam University Medical Centers, location VUmc, Postbox 7507, 1007MB Amsterdam, The Netherlands; Department of Intensive Care Medicine, Amsterdam University Medical Centers, location VUmc, Postbox 7507, 1007MB Amsterdam, The Netherlands; Aix Marseille Université , Center for Cardiovascular and Nutrition Research (C2VN), INSERM, INRAE, and Service d’Explorations Fonctionnelles Respiratoires, CHU Nord, Assistance Publique Des Hô pitaux de Marseille, Marseille, France; AP-HP, Groupe Hospitalier Universitaire APHP-Sorbonne Université , Site Pitié -Salpê triè re, Service de Mé decine Intensive Et Ré animation (Dé partement R3S), and Sorbonne Université , INSERM, UMRS1158 Neurophysiologie Respiratoire Expé rimentale Et Clinique, 75005 Paris, France; AP-HP, Groupe Hospitalier Universitaire APHP-Sorbonne Université , Site Pitié -Salpê triè re, Service de M&ea; (Critical care : CC, v.26, 2022, pp.99)
QUICK MENU
